{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-275336","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.653322+00:00","generated_at":"2026-06-22T14:25:50.220365+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Silverback Therapeutics announces final exchange ratio of 1.1819 for merger with ARS Pharma","bullets":["Final exchange ratio set at 1.1819 per the Merger Agreement as amended on October 25, 2022.","Merger with ARS Pharmaceuticals remains subject to stockholder approval and other closing conditions.","Shareholders are urged to read the definitive proxy statement filed on October 6, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-275336","json":"https://secwatch.observer/filing/0001193125-22-275336.json","markdown":"https://secwatch.observer/filing/0001193125-22-275336.md","text":"https://secwatch.observer/filing/0001193125-22-275336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/0001193125-22-275336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/d408267d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:25:50.220365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}